Physician profile
Michael W Chen
NPI 1205859170
$9,392.78
in general payments reported to CMS, 2019-2025
51 companies · $2,952 in 2025
The $2,952 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $372 · 2021: $12.08 · 2022: $1,233 · 2023: $1,484 · 2024: $2,471 · 2025: $2,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,906.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,273.29 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Lilly USA, LLC | $824.22 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Ucb, INC. | $586.27 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Lundbeck LLC | $514.72 | 2022-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $426.24 | 2019-2025 | |
| Eisai INC. | $422.80 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $399.00 | 2019-2025 | Nuplazid |
| Pfizer INC. | $369.00 | 2022-2025 | |
| Amgen INC. | $330.72 | 2019-2024 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $318.60 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $258.18 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $240.96 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $217.96 | 2024-2025 | Acthar |
| Biogen, INC. | $152.52 | 2019-2024 | Vumerity, Skyclarys, Spinraza |
| Adamas Pharmaceuticals, INC. | $151.20 | 2019-2020 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $147.21 | 2022-2025 | |
| Mdd US Operations, LLC | $142.56 | 2019-2025 | Gocovri, Gocovri |
| Biohaven Pharmaceutical Holding Company Ltd. | $141.15 | 2022 | |
| Celgene Corporation | $123.62 | 2022-2025 | Zeposia |
| Harmony Biosciences LLC | $101.37 | 2023-2024 | Wakix |
| Catalyst Pharmaceuticals, INC. | $100.01 | 2023-2024 | Fycompa |
| Alexion Pharmaceuticals, INC. | $87.80 | 2024-2025 | Ultomiris |
| Genzyme Corporation | $81.66 | 2019-2022 | |
| Kyowa Kirin, INC. | $75.31 | 2022-2024 | Nourianz |
| Axsome Therapeutics, INC. | $71.28 | 2025 | Symbravo |
| Argenx US, INC. | $69.44 | 2025 | |
| Tanabe Pharma America, INC. | $59.68 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $58.77 | 2024-2025 | Wainua |
| Grifols USA, LLC | $53.40 | 2024 | Gamunex-C |
| Emd Serono, INC. | $50.66 | 2022-2023 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $45.42 | 2020-2022 | |
| Allergan, INC. | $44.14 | 2020 | |
| Avanir Pharmaceuticals, INC. | $43.53 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $40.44 | 2025 | Rexulti, Nuedexta |
| Baxter Healthcare | $34.50 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Amneal Pharmaceuticals LLC | $32.12 | 2020-2023 | Rytary |
| Janssen Pharmaceuticals, INC | $29.37 | 2025 | Spravato |
| Vertical Pharmaceuticals, LLC | $28.75 | 2019-2020 | |
| Greenwich Biosciences, INC. | $25.49 | 2019 | |
| Neurelis, INC. | $25.00 | 2024 | Valtoco |
| Genentech USA, INC. | $23.23 | 2025 | Ocrevus Zunovo |
| Scilex Pharmaceuticals INC. | $22.77 | 2024 | |
| Azurity Pharmaceuticals, INC. | $22.24 | 2024 | Horizant |
| Arbor Pharmaceuticals, INC. | $18.78 | 2022 | |
| Kedrion Biopharma, INC. | $18.22 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Banner Life Sciences, LLC | $17.95 | 2023 | |
| Abbott Laboratories | $17.52 | 2024 | Infinity |
| Impel Pharmaceuticals INC. | $16.58 | 2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $16.14 | 2025 | Amvuttra |
| Ge Healthcare | $11.73 | 2020 | |
| Bio Products Laboratory USA, INC. | $9.26 | 2023 | Coagadex, Gammaplex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.